|
1
|
Cohn SL, Pearson AD, London WB, et al: The
International Neuroblastoma Risk Group (INRG) classification
system: an INRG Task Force report. J Clin Oncol. 27:289–297. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brodeur GM, Seeger RC, Schwab M, Varmus HE
and Bishop JM: Amplification of N-myc in untreated human
neuroblastomas correlates with advanced disease stage. Science.
224:1121–1124. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Seeger RC, Brodeur GM, Sather H, et al:
Association of multiple copies of the N-myc oncogene with
rapid progression of neuroblastomas. New Engl J Med. 313:1111–1116.
1985.PubMed/NCBI
|
|
4
|
Wang LL, Suganuma R, Ikegaki N, et al:
Neuroblastoma of undifferentiated subtype, prognostic significance
of prominent nucleolar formation, and MYC/MYCN protein expression:
a report from the Children’s Oncology Group. Cancer. 119:3718–3726.
2013.PubMed/NCBI
|
|
5
|
Kucab JE, Lee C, Chen CS, et al: Celecoxib
analogues disrupt Akt signaling, which is commonly activated in
primary breast tumours. Breast Cancer Res. 7:R796–R807. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhu J, Huang JW, Tseng PH, et al: From the
cyclooxygenase-2 inhibitor celecoxib to a novel class of
3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer
Res. 64:4309–4318. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sears R, Nuckolls F, Haura E, Taya Y,
Tamai K and Nevins JR: Multiple Ras-dependent phosphorylation
pathways regulate Myc protein stability. Genes Dev. 14:2501–2514.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Adhikary S and Eilers M: Transcriptional
regulation and transformation by Myc proteins. Nat Rev Mol Cell
Biol. 6:635–645. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schulein C and Eilers M: An unsteady
scaffold for Myc. EMBO J. 28:453–454. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marampon F, Ciccarelli C and Zani BM:
Down-regulation of c-Myc following MEK/ERK inhibition halts the
expression of malignant phenotype in rhabdomyosarcoma and in non
muscle-derived human tumors. Mol Cancer. 5:312006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang H, Liu Q, Cheng GZ, He L, Nicosia SV
and Cheng JQ: Crosstalk between Aurora-A and GSK3β/β-catenin
pathways induces c-Myc and cyclin D1. Proc Amer Assoc Cancer Res.
46:55072005.
|
|
12
|
Tang XX, Zhao H, Robinson ME, et al:
Implications of EPHB6, EFNB2, and EFNB3 expressions
in human neuroblastoma. Proc Natl Acad Sci USA. 97:10936–10941.
2000.
|
|
13
|
Regan PL, Jacobs J, Wang G, et al: Hsp90
inhibition increases p53 expression and destabilizes MYCN and MYC
in neuroblastoma. Int J Oncol. 38:105–112. 2011.PubMed/NCBI
|
|
14
|
Torres J, Regan PL, Edo R, et al:
Biological effects of induced MYCN hyper-expression in
MYCN-amplified neuroblastomas. Int J Oncol. 37:983–991.
2010.PubMed/NCBI
|
|
15
|
Cancilla MT, He MM, Viswanathan N, et al:
Discovery of an Aurora kinase inhibitor through site-specific
dynamic combinatorial chemistry. Bioorg Med Chem Lett.
18:3978–3981. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Harrington EA, Bebbington D, Moore J, et
al: VX-680, a potent and selective small-molecule inhibitor of the
Aurora kinases, suppresses tumor growth in vivo. Nat Med.
10:262–267. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yacoub A, Park MA, Hanna D, et al:
OSU-03012 promotes caspase-independent but PERK-, cathepsin B-,
BID-, and AIF-dependent killing of transformed cells. Mol
Pharmacol. 70:589–603. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sawyer TK, Wu JC, Sawyer JR and English
JM: Protein kinase inhibitors: breakthrough medicines and the next
generation. Expert Opin Investig Drugs. 22:675–678. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bain J, Plater L, Elliott M, et al: The
selectivity of protein kinase inhibitors: a further update. Biochem
J. 408:297–315. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tyler RK, Shpiro N, Marquez R and Eyers
PA: VX-680 inhibits Aurora A and Aurora B kinase activity in human
cells. Cell Cycle. 6:2846–2854. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Segerstrom L, Baryawno N, Sveinbjornsson
B, et al: Effects of small molecule inhibitors of PI3K/Akt/mTOR
signaling on neuroblastoma growth in vitro and in
vivo. Int J Cancer. 129:2958–2965. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Otto T, Horn S, Brockmann M, et al:
Stabilization of N-Myc is a critical function of Aurora A in human
neuroblastoma. Cancer Cell. 15:67–78. 2009. View Article : Google Scholar : PubMed/NCBI
|
